FIELD: medicine.
SUBSTANCE: group of inventions relates to the treatment of arthritis. Disclosed is the use of a compound of Formula (II), including tautomeric forms thereof, enantiomeric forms, diastereomeric forms and racemic forms, or a pharmaceutically acceptable salt thereof:
in combination with methotrexate (MTX), or a prodrug thereof, for the treatment of arthritis, wherein methotrexate (MTX), or a prodrug thereof, is administered in an amount of about 1 to about 30 mg per week and the compound of formula (II) is administered in an amount of about 1 mg to about 1000 mg per day. Also disclosed is a combination for treating arthritis.
EFFECT: group of inventions provides a significantly stronger anti-arthritic action compared to the action of each of the compounds separately.
54 cl, 3 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROTEINURIA TREATMENT | 2019 |
|
RU2805150C2 |
| PHARMACEUTICAL COMPOSITION INCLUDING A HISTONE DEACETYLASE INHIBITOR AND METHOTREXATE | 2019 |
|
RU2772018C1 |
| METHODS OF DIAGNOSING AND TREATING RHEUMATOID ARTHRITIS | 2020 |
|
RU2828027C2 |
| GM-CSF-NEUTRALIZING ANTIBODIES FOR USE IN TREATING RHEUMATOID ARTHRITIS OR AS ANALGESICS | 2014 |
|
RU2714919C2 |
| COMPOSITION FOR TREATING DISEASE | 2009 |
|
RU2531548C2 |
| METHODS OF TREATING RHEUMATOID ARTHRITIS USING IL-17 ANTAGONISTS | 2011 |
|
RU2582937C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF LEVILIMAB AND THE USE THEREOF | 2020 |
|
RU2745814C1 |
| METHODS FOR TREATING METHOTREXATE-RESISTANT DISORDERS WITH 10-PROPARGYL-10-DEAZAAMINOPTERIN | 2011 |
|
RU2586299C2 |
| MEDICAL PRODUCT AND METHOD OF RHEUMATIC DISEASES TREATMENT | 2006 |
|
RU2330664C2 |
| METHOD OF TREATING PATIENTS WITH RHEUMATOID ARTHRITIS | 2013 |
|
RU2554232C1 |
